carvedilol or metoprolol succinate

Carvedilol or metoprolol succinate refers to the use of either carvedilol or the extended-release formulation of metoprolol (metoprolol succinate), both of which are beta-blockers indicated for the treatment of heart failure with reduced ejection fraction (HFrEF), hypertension, and left ventricular dysfunction following myocardial infarction. Carvedilol is a non-selective beta blocker that also blocks alpha-1 adrenergic receptors, providing vasodilating properties in addition to its effects on heart rate and contractility. Metoprolol succinate is a selective beta-1 adrenergic receptor blocker that primarily affects cardiac tissue with less effect on bronchial and vascular smooth muscle. Both drugs reduce morbidity and mortality in patients with HFrEF when used as part of guideline-directed medical therapy[1][6][8]. They are also approved for hypertension and post-myocardial infarction management, with additional off-label uses including arrhythmias such as atrial fibrillation[1][8].

Other names

carvedilolmetoprolol succinate